146 related articles for article (PubMed ID: 28461099)
1. Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
Alaaeldin E; Abu Lila AS; Ando H; Fukushima M; Huang CL; Wada H; Sarhan HA; Khaled KA; Ishida T
J Control Release; 2017 Jun; 255():210-217. PubMed ID: 28461099
[TBL] [Abstract][Full Text] [Related]
2. The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.
Alaaeldin E; Abu Lila AS; Moriyoshi N; Sarhan HA; Ishida T; Khaled KA; Kiwada H
Pharm Res; 2013 Sep; 30(9):2344-54. PubMed ID: 23673556
[TBL] [Abstract][Full Text] [Related]
3. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
4. Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy.
Abu Lila AS; Fukushima M; Huang CL; Wada H; Ishida T
Mol Pharm; 2016 Nov; 13(11):3955-3963. PubMed ID: 27740765
[TBL] [Abstract][Full Text] [Related]
5. A simplified method for manufacturing RNAi therapeutics for local administration.
Ando H; Abu Lila AS; Fukushima M; Matsuoka R; Shimizu T; Okuhira K; Ishima Y; Huang CL; Wada H; Ishida T
Int J Pharm; 2019 Jun; 564():256-262. PubMed ID: 31015002
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
[TBL] [Abstract][Full Text] [Related]
8. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
9. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
Ando H; Abu Lila AS; Tanaka M; Doi Y; Terada Y; Yagi N; Shimizu T; Okuhira K; Ishima Y; Ishida T
Mol Pharm; 2018 Feb; 15(2):403-409. PubMed ID: 29287147
[TBL] [Abstract][Full Text] [Related]
11. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.
Shimizu T; Abu Lila AS; Nishio M; Doi Y; Ando H; Ukawa M; Ishima Y; Ishida T
Cancer Sci; 2017 Sep; 108(9):1864-1869. PubMed ID: 28643902
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
Iizuka K; Jin C; Eshima K; Hong MH; Eshima K; Fukushima M
Drug Des Devel Ther; 2018; 12():673-683. PubMed ID: 29636601
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
Abu Lila AS; Kato C; Fukushima M; Huang CL; Wada H; Ishida T
Int J Oncol; 2016 Apr; 48(4):1399-407. PubMed ID: 26847426
[TBL] [Abstract][Full Text] [Related]
14. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Doi Y; Okada T; Matsumoto H; Ichihara M; Ishida T; Kiwada H
Cancer Sci; 2010 Nov; 101(11):2470-5. PubMed ID: 20731663
[TBL] [Abstract][Full Text] [Related]
19. Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
Abu Lila AS; Moriyoshi N; Fukushima M; Huang CL; Wada H; Ishida T
Cancer Lett; 2017 Aug; 400():223-231. PubMed ID: 27838412
[TBL] [Abstract][Full Text] [Related]
20. Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: Long-term silencing and anticancer effects in vivo.
Seraj S; Lee J; Ahn HJ
Biochem Pharmacol; 2019 Aug; 166():192-202. PubMed ID: 31129050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
